
Phreesia Inc (PHR) Stock Forecast & Price Target
Phreesia Inc (PHR) Analyst Ratings
Bulls say
Phreesia is a healthcare technology company that provides an integrated software platform designed to improve access to care, affordability of care, and patient health outcomes. The recent acquisition of AccessOne has been performing as expected, with high rates of providers giving permission for pharma ads on the platform and strong demand among large healthcare organizations. However, the company's top-line deceleration puts its "Rule of 40" objective in jeopardy, potentially impacting its valuation. As a result, analysts have raised their revenue and EBITDA estimates for FY27, but still see shares as fairly valued at current levels given uncertainties.
Bears say
Phreesia is facing several headwinds, including a decline in subscription revenue and slower provider adds due to more aggressive pricing. Furthermore, there are concerns about the company's ability to retain clients and cross-sell to larger health system clients. Additionally, Phreesia's acquisition of AccessOne has not been performing well, with shrinking revenue and net income, and there is ongoing litigation related to the 2024 outage of ConnectOnCall. These factors suggest a negative outlook for the company's future financial performance.
This aggregate rating is based on analysts' research of Phreesia Inc and is not a guaranteed prediction by Public.com or investment advice.
Phreesia Inc (PHR) Analyst Forecast & Price Prediction
Start investing in Phreesia Inc (PHR)
Order type
Buy in
Order amount
Est. shares
0 shares